Menu Close

Get Inspired By 27 Speakers Including Pfzier, Novartis, Astellas, Ipsen, Teva & More As They Reveal How To Drive Patient Centricity & Engagement With Meaningful Patient Involvement

Drive Patient Centricity & Engagement With Meaningful Patient Involvement: Embed Patients At the Heart of Decision Making With Actionable Strategies Which Inform Clinical Trial Design, Drug Development & Commercial Success With Early Patient Involvement, Patient Journey Insights, Meaningful Partnerships, Digital & Tech Innovations & Stakeholder Collaboration

A One-Day Conference & Networking Event, 19th May 2019, Central London

08.30 Registration, Coffee & Informal Networking

09.00 GIC Welcome, Interactive Voting Introduction & Morning Co-Chairs’ Opening Remarks

Anand Das
Regional Client Partner
Pfizer UK

Dirk Abeel
Global Medical Sales Director
Reckitt Benckiser

Patient Insight

09.10 It’s Time To Think Practically! Actionable Insights Into Using Patient Data & Feedback To Improve Patient Welfare & Strategic Success

  • You want to support patients, but there’s so many rules and regulations! How can pharma gain real insights into patient needs and understand their journey with limited data access?
  • How can the industry better understand the patient voice to deliver what patients want and need to improve patient outcomes?
  • What tools are out there to tackle patient data, information and feedback and translate them into real life, applicable insights and action plans?
  • Benchmarking patient engagement levels throughout to determine to what extent your activities are making a difference

Philibert Goulet
Head of Vaccines Patient Office
GSK

The Patient Journey - Q&A Panel

09.30 High-Impact Strategies To Improve The End-To-End Patient Journey: How Can Pharma Improve Patient Experience?

  • Beyond the pill! Examining opportunities in the patient journey to determine where pharma can most tangibly improve patient experiences and commercial success
  • Combatting misinformation by uncovering where patients seek information and equipping patients with accessible, easily digestible information from day one to empower them to make their own decisions
  • How can you accurately measure and determine the value that your strategies are adding to the patient – and the business?

Ulrike Towanou
Head of Patient Services Germany & Austria
Teva Speciality Medicines

Mohammed Rahman
Associate Director – Distribution Strategy & PSPs
Bristol-Myers Squibb

Lu Zheng
Senior Director Head of Global Strategic Patient Services
Takeda

Lara Pippo
Head of Market Access & Government Affairs
CSL Behring

Early Patient Involvement In Clinical Trials

10.00 Strategies To Engage Patients Early On In Clinical Trial Design & Drug Development To Ensure Faster, More Effective Market Access & Better Patient Outcomes

  • Practical steps to improve patient recruitment and increase adherence and retention to ensure accurate testing, produce optimal products and enable drugs to get from lab to shelf as quickly as possible
  • Meaningful methods to involve patients from the start and post-trial to gain real-world evidence and incorporate impactful, value-adding patient feedback into drug development
  • How can patients be encouraged to participate in the creation of new medical devices, apps and digital health to enrich business and patient outcomes?
  • Closing the loop – how can pharma brands build a community and better relay the outcomes of a clinical trial to the patient volunteers?

Oleksandr Gorbenko
Global Patient Centricity Director
Ipsen


10.45 Morning Refreshment Break With Informal Networking

Patient Feedback - Panel 

10.50 The Patient Platform: Sharing Insights & Feedback Around Patient Motivations, Wellbeing, Preferences & Experiences

  • What has motivated you to be here today and want to directly engage with the industry?
  • What have been the highs and lows of your experiences and relationships with pharma?
  • Patient reported outcomes are great, but what do you as patients consider value adding?
  • How can pharma continue to encourage patients to actively participate in the end-to-end clinical trials process?
  • Where do you think opportunities lie for pharma to positively impact your treatment and wider wellbeing?

Lorna Allen
PPI Coordinator for the Clinical Trials Accelerator Platform
Cystic Fibrosis Trust

Dany Bell
Strategic Advisor Treatment, Medicines & Genomics
Macmillan Cancer Support

Garry Brough
Lead for Peer Learning, Partnerships & Policy
Positively UK

Olive Fulton
Patient Advocate
Asthma UK Centre for Applied Research

Amena Warner
Head of Clinical Services
Allergy UK


11.20 Bonus Session: Reserved For Exclusive Conference Partner. For more information on how to get involved, please call +44 (0)20 3479 2299 or email partner@patientengagementconference.com.

Patient Advocacy Partnerships

11.50 Forming Strong, Meaningful & Long-Lasting Strategic Patient-Pharma Partnerships Which Add Value To Patients & Pharma Alike

  • Just how do you go about forming a partnership? From identifying the right partners to co-creating strategic relationships with longevity, how has the relationship evolved?
  • Manage expectations to work together towards a common goal and raise greater awareness of the disease, improve quality of life and treatment options and provide support from day one
  • The success stories! How to maintain a successful partnership beyond the honeymoon period and secure an ongoing collaboration with measurable impact?
  • Evidence the value created for patients, the healthcare system and pharmaceuticals

Geoff Rollason
Patient Experiences & Service Director
Pfizer UK

Catherine Wood
Head of Services Improvement
Breast Cancer Now

Internal & Patient Collaboration - Case Study

12.10 In-Depth Haematology Case Study

Internal Collaboration Between Medical & Patient Engagement Functions For In-Depth, Value-Adding Patient Insights & Outcomes

Michael Zaiac
ORE Medical Affairs Head
Novartis

Veronica Foote
Head of Patient Relations & Communications
Novartis


12.30 Lunch For Delegates, Speakers & Partners

Informal Peer-To-Peer Discussions

13.00 Informal Peer-To-Peer Discussions

A) Oncology

B) Rare Diseases

C) Chronic Illness

D) Mental Health

E) Reimbursement

F) Market Access


13.30 Afternoon Co-Chair’s Opening Remarks

Paul Edwards
Director of Clinical Services
Dementia UK

Collaborating With Stakeholders - Q&A Panel

13.40 Tangible Techniques To Overcome Blockers, Achieve Strong Collaborative Relationships & Align Multiple Stakeholders Behind The Patient

  • From industry to patient advocacy groups to regulators to healthcare and government; we’ve all got our own agendas, but how can we best collaborate and refocus on the patient?
  • How can we better understand different objectives and priorities and communicate effectively to manage expectations and align to one another?
  • Learning from one another! Sharing best practice, innovations and patient strategies which have delivered real impact

Esther Wong
Lead Pharmacist – Medicines Information, Neurology & IVIg
Chelsea & Westminster NHS Foundation Trust

Chris Macdonald
Head of Research
Pancreatic Cancer UK

Mary Uhlenhopp
RN, MS, MPH Head (Sr Dir), Global Advocacy
Takeda

Andras Fehervary
Executive Director, Advocacy Relations
Amgen

Digital & Tech 

14.10 Seizing Opportunities In Digital & Tech To Improve Patient Experiences, Engagement & Support

  • Ensuring that the patient is considered on every channel: we can’t talk to them, but we really need to ensure that they buy into what we say about them!
  • What exactly is involved in HTA reform and where does the patient voice fit into this?
  • Closing the gap between what patients need and what pharma believes they need to deliver medical devices, digital and technological support and add value to patients
  • Looking to the future and how technology is changing patient care

Bas van Heijst
Associate Regulatory Affairs Director
Astellas


14.30 Bonus Session: Reserved For Exclusive Conference Partner.For more information on how to get involved, please call +44 (0)20 3479 2299 or email partner@patientengagementconference.com.


15.10 Afternoon Refreshment Break With Informal Networking

Overcoming Barriers To Patient Centricity - Q&A Panel

15.40 Overcome Internal & Industry Barriers To Ensure Genuine Patient Centricity, Embed The Patient At The Heart Of The Business & Commit To More

  • Break down those barriers! Challenge internal apathy and demonstrate the value and commercial benefits of consistent patient involvement to secure senior buy-in and thoroughly embed patient centricity in your organisation
  • Navigate patient expectations, regulation, internal policies and communications barriers to successfully execute patient strategies
  • Go beyond paying lip service: how can you ascertain that your internal patient support is actually translating to better patient outcomes?

Michaela Dinböck
Senior Director, Group Patient Advocacy
Novartis

Dirk Abeel
Global Medical Sales Director
Reckitt Benckiser

James Fitzpatrick
Head of Patient Engagement & Government Affairs
Janssen

Chetak Buaria
Global Head of Commercial Excellence
Merck

Safeguarding Patients

16.10 Consider Patient Needs Beyond Treatment & Health: Actionable Measures To Positively Impact Patient Safety, Data & Wellbeing

  • How can you ensure that patient safety is at the forefront of every internal process?
  • Navigating the world of data! How can you compliantly and ethically collect and manage patient data to ensure their privacy and integrity?
  • Beyond the pill, beyond the disease, beyond the treatment: ensure you are seeing the full patient picture and considering wellbeing factors from mental health, to pain management, to quality of life

Kristin Janett Løseth
Director; Medical Information, Patient Safety & Ethics
AstraZeneca


16.30 Co-Chairs’ Closing Remarks


16.45 Official Close Of Conference

5 ACROSS